Amgen quietly kills an obesity program, casting bleak future for once-promising target

Five years ago, in a span of less than two months, four drug companies simultaneously converged on a single new way to treat obesity.

It was a curious scientific journey. More than a decade prior, an Australian immunologist named Sam Breit had shown